Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Medical technology company CareFusion (CFN - Snapshot Report) recently announced an agreement for the acquisition of privately-owned Brazilian company, Intermed Equipamento Medico Hospitalar Ltda. Sao Paulo-based Intermed is a developer, manufacturer and supplier of medical equipment for use in respiratory care including ventilators and accessories for ventilation across Latin America.
The acquisition is expected to go through during CareFusion’s second quarter fiscal 2013, subject to customary conditions. However, the financial terms of the agreement remain undisclosed.
Though the acquisition will be slightly dilutive to CareFusion’s fiscal 2013 earnings, it is expected to have a neutral impact on earnings for fiscal 2014.
CareFusion is targeting a 12−14% compounded earnings per share growth through fiscal 2015 on the back of capital allocation in the form of suitable acquisitions and share buyback programs. The upcoming acquisition of Intermed is in line with the company’s strategy.
Brazil is one of the largest economies with a flourishing healthcare sector, backed by government investments, burgeoning middle class and higher formal employment. Thus, the acquisition is a worthy investment in a high-value market as it is expected to be accretive to CareFusion’s top-line by generating $25 million annually.
Going forward, CareFusion will accelerate its globalization strategy and leverage sales for its Respiratory Technologies business. The company reported 3% year over year revenue growth to gross $968 million in the fourth quarter of fiscal 2012. It recorded 29% sales growth in Respiratory Technologies in the quarter. CareFusion also witnessed notable growth in the BRIC nations in the most recent quarter.
Intermed is, thus a strategic fit in CareFusion’s existing respiratory product platform. The acquisition underlines the company’s efforts in expanding its foothold in the international market, especially Latin America and other emerging markets.
CareFusion continues to build a solid foundation for future growth. The company faces competition from Baxter International (BAX - Analyst Report) and Becton, Dickinson and Company (BDX - Analyst Report) among others. While a slew of product recalls represent a downside, CareFusion is growing both through the organic and the inorganic route.
We currently have a long-term Neutral recommendation on CareFusion, supported by a short-term Zacks #1 Rank (Strong Buy).
Get the full Snapshot Report on CFN - FREE
Get the full Analyst Report on BDX - FREE
Get the full Analyst Report on BAX - FREE